Notice of Class Action Lawsuit for Embecta Shareholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Embecta Corp. (NASDAQ: EMBC) common stock between November 25, 2025, and May 4, 2026, to apply as lead plaintiffs by August 17, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Embecta made false or misleading statements regarding its financial results, leading to investor losses when the company failed to meet expectations and cut its 2026 fiscal guidance, highlighting significant management failures.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and resource advantages in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EMBC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EMBC
About EMBC
Embecta Corp. is a global medical device company. It provides solutions to improve the health and well-being of people living with diabetes. Its portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It distributes its products through channels, including retail, hospitals and pharmacies. It is also a manufacturer of medical devices and drug delivery technologies.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Promise vs. Reality Gap: Embecta initially projected flat-to-down 2% revenue for FY 2026, yet reported a staggering 17.4% revenue decline, indicating a significant misjudgment by management regarding market conditions, which severely undermined investor confidence.
- Earnings Guidance Cut: The company slashed its adjusted EPS forecast from 2.80-3.00 to 1.55-1.75, nearly halving expectations, which directly impacted shareholder returns with a loss of $5.35 per share in a single trading session.
- Stock Price Volatility: On May 5, 2026, Embecta's stock plummeted from $9.25 to $3.90, a dramatic 57.8% drop, reflecting the market's extreme pessimism about the company's future prospects.
- Legal Action Initiated: Investors have filed a class-action lawsuit against Embecta for failing to disclose market risks accurately, holding management accountable, which is expected to have long-term negative implications for the company's reputation and future financing capabilities.
See More
- Class Action Notice: Rosen Law Firm reminds investors who purchased Embecta Corp. (NASDAQ: EMBC) common stock between November 25, 2025, and May 4, 2026, to apply as lead plaintiffs by August 17, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Embecta made false or misleading statements regarding its financial results, leading to investor losses when the company failed to meet expectations and cut its 2026 fiscal guidance, highlighting significant management failures.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and resource advantages in handling such cases.
See More

- Lawsuit Background: Embecta Corp. is facing a securities class action lawsuit following its disastrous Q2 2026 earnings report, which represents investors who purchased stock between November 25, 2025, and May 4, 2026, highlighting severe investor concerns regarding the company's financial health.
- Deteriorating Financial Performance: The company reported an adjusted EPS of only $0.27 for Q2 2026, a staggering year-over-year decline of approximately 61%, starkly contrasting with prior guidance of $2.80 to $3.00 for 2026, leading to a significant drop in market confidence regarding its future profitability.
- Severe Market Reaction: Following the earnings report, Embecta's stock price plummeted, with analysts noting that the management needs to rebuild investor credibility regarding commercial execution and profitability outlook, reflecting market skepticism about the company's transparency and risk management.
- Significant Dividend Cut: Embecta slashed its 2026 adjusted EPS guidance to $1.55 to $1.75 and reduced its dividend by 93% to just $0.01, indicating financial strain in addressing market challenges and insufficient commitment to shareholder returns.
See More
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Embecta Corp, alleging violations of federal securities laws during the period from November 25, 2025, to May 4, 2026, seeking damages for affected investors.
- False Statements Allegations: The complaint claims that Embecta made materially false and misleading statements about its business, particularly asserting that its pen needle business was 'incredibly resolute' just weeks before it missed expectations and cut its fiscal guidance for 2026.
- Revenue Decline: Embecta's Q2 2026 results revealed a revenue decline of over 14%, significantly worse than its guidance of flat to a 2% decline, indicating substantial weaknesses in its U.S. performance, particularly in pen needle sales.
- Investor Action Encouraged: Affected investors are urged to apply to be lead plaintiffs by August 17, 2026, to participate in any potential recovery, with the law firm operating on a contingency fee basis, thus minimizing financial risk for investors.
See More
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Embecta Corp for violations of §§10(b) and 20(a) of the Securities Exchange Act, involving securities purchased between November 25, 2025, and May 4, 2026, with a deadline to contact the firm by August 17, 2026.
- False Statement Allegations: The complaint alleges that Embecta made false and misleading statements regarding its fiscal guidance for Q2 and full-year 2026, creating a misleading impression that it had a reliable basis for its forecasts, despite knowing that market headwinds would likely impact performance.
- Market Reaction Impact: When the market learned the truth about Embecta, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, which could lead to a decline in investor confidence and affect the stock price.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits aimed at helping investors recover losses.
See More
- Lawsuit Background: Robbins LLP reminds all stockholders who purchased or acquired Embecta Corp. (NASDAQ: EMBC) securities between November 25, 2025, and May 4, 2026, that a class action has been filed against the company, alleging it misled investors regarding its business prospects.
- Performance Guidance Failure: The complaint states that during the class period, Embecta continuously reaffirmed its revenue guidance for fiscal year 2026, but on May 5, 2026, it reported failing to meet its second-quarter guidance and lowered its full-year guidance by 46%, primarily due to weak pen needle sales.
- Stock Price Plunge: Following the negative news, Embecta's stock price fell over 57% to $3.90 per share on May 5, 2026, reflecting significant market concerns about the company's financial health and future prospects.
- Shareholder Action: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by August 17, 2026, indicating their willingness to represent other shareholders in the litigation, while those who choose not to participate can remain absent class members and still retain their rights to recovery.
See More





